摘要
目的探讨EphB6蛋白在结直肠癌中的表达及其临床意义。方法采用免疫组织化学染色检测82例结直肠癌组织与癌旁组织中EphB6蛋白的表达,并比较两者表达的差异;分析EphB6蛋白与结直肠癌临床病理特征的关系;分析有随访资料的49例患者EphB6蛋白表达与预后的关系。结果与癌旁组织相比,结直肠癌组织EphB6蛋白表达下调40例(48.8%),表达上调14例(17.1%),无变化28例(37.1%)。结直肠癌组织EphB6蛋白表达下调者多为中晚期(P=0.015)或淋巴结转移者(P=0.048),但与肿瘤分化无明显相关。结直肠癌组织EphB6蛋白表达下调组和无变化组的中位生存时间分别为34个月和33个月,上调组的生存时间较长(中位生存时间为未达到),3组差异接近有统计学意义(P=0.052)。结论EphB6基因在结直肠癌的发展过程中可能有一定抑制肿瘤转移及发展的作用,该蛋白有可能成为结直肠癌预后的新指标。
Objective To investigate the expression level of EphB6 in colorectal carcinoma（CRC）and its association with clinical parameters.Methods Immunohistochemical staining was conducted to detect expression level of EphB6 protein in 82 colorectal cancer tissue specimens.Expression level of EphB6 in tumor tissues was compared with expression level in corresponded normal tissues.The clinical significances of down-regulation of EphB6 expression were analyzed.Survival analysis was employed for analyzing the correspondence between down-regulation of EphB6 expression in tumor tissues and patients＇ survival.Results According to the expression rates in normal and tumor tissues,the expression level of EphB6 in CRC was divided into 3 groups,up-regulation（n=14）,no change（n=28） and down-regulation（n=40）,respectively.The immunohistochemical staining result for EphB6 was punctiform positive in cytoplasm.Down-regulation of expression was related to clinical stage（P=0.015） and lymph gland metastasis（P=0.048）.Survival analysis probably showed a different prognosis among three groups（P=0.052）.The median survival of the down-regulation group and no change group was 34 months and 33 months,respectively.Conclusion Down-regulation of expression of EphB6 may promote progression and metastasis of CRC and be a new biomarker of prognosis.
出处
《临床肿瘤学杂志》
CAS
2012年第3期198-201,共4页
Chinese Clinical Oncology
基金
国家自然科学基金资助项目(30970813
30930028
81171391)
